Simplified regimen of combined low-dose rituximab for autoimmune encephalitis with neuronal surface antibodies

被引:7
作者
Du, Ying [1 ]
Zhao, Chao [1 ]
Liu, Juntong [1 ]
Li, Chuan [1 ]
Yan, Qi [1 ]
Li, Lin [1 ]
Hao, Yunfeng [1 ]
Yao, Dan [1 ]
Si, Huaxing [1 ]
Zhao, Yingjun [2 ]
Zhang, Wei [1 ]
机构
[1] Fourth Mil Med Univ, Tangdu Hosp, Dept Neurol, Xian 710038, Shaanxi, Peoples R China
[2] Xiamen Univ, Sch Med, Inst Neurosci, Fujian Prov Key Lab Neurodegenerat Dis & Aging Re, Xiamen 361005, Peoples R China
基金
中国国家自然科学基金;
关键词
Autoimmune encephalitis; Neuronal surface antibody; Rituximab; Low dose; Combined treatment; Clinical outcome; NMDA-RECEPTOR ENCEPHALITIS; MECHANISMS; PROTEINS;
D O I
10.1186/s12974-022-02622-8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Autoimmune encephalitis (AE) with neuronal surface antibodies (NSAbs) presents pathogenesis mediated by B cell-secreting antibodies. Rituximab is a second-line choice for the treatment for AE with NSAbs, which can cause B cell depletion via targeting CD20. However, the optimal protocol and dosage of rituximab combined with first-line therapy for NSAbs-associated AE remains unclear so far. In this study, we explored the efficacy and safety of low-dose rituximab combined with first-line treatment for NSAbs-associated AE. Methods Fifty-nine AE patients with NSAbs were enrolled, and retrospectively divided into common first-line therapy (41 patients) and combined low-dose rituximab (100 mg induction weekly with 3 circles, followed by 100 mg reinfusion every 6 months) with first-line therapy (18 patients). Outcome measures included changes in the Clinical Assessment Scale for Autoimmune Encephalitis (CASE) score (primary endpoint), changes in the modified Rankin Scale (mRS), the Mini-mental State Examination (MMSE), the patient and caregiver Neuropsychiatric Inventory (NPI) score at each visit (baseline, discharge, 6 months, 12 months and last follow-up) between two groups (secondary endpoint), as well as oral prednisone dosage, relapse and adverse effects during follow-up. Results Compared with traditional first-line therapy group, for primary outcome, CASE scores at last follow-up were significantly improved in combined rituximab group, as well as markedly improving changes of CASE scores between baseline and each visit. While changes of mRS, MMSE and NPI scores, as secondary endpoint, were all markedly accelerating improvement between baseline and each visit, as well as both oral prednisone dosage and relapse were also greatly reduced during follow-up. Meanwhile, longitudinal analysis in combination of rituximab cohort also revealed persistently marked amelioration in a series of scales from baseline even more than 1 year. Moreover, analysis in rituximab subgroup showed no difference in any clinical outcomes between combination with single first-line and with repeated first-line treatment (>= 2 times), while compared to delayed combination with rituximab (> 3 months), early initiation of combination (<= 3 months) might achieve better improvements in CASE and MMSE assessment even 1 year later. No rituximab-correlated serious adverse events have been reported in our patients. Conclusions Our simplified regimen of combined low-dose rituximab firstly showed significantly accelerating short-term recovery and long-term improvement for AE with NSAbs, in parallel with markedly reduced prednisone dosage and clinical relapses. Moreover, opportunity of protocol showed earlier initiation (<= 3 months) with better long-term improvement.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Low-dose rituximab treatment in a patient with anti-neurofascin-155 IgG4 autoimmune nodopathy
    Kmezic, Ivan
    Press, Rayomand
    Glenewinkel, Helena
    Doppler, Kathrin
    Appeltshauser, Luise
    JOURNAL OF NEUROIMMUNOLOGY, 2024, 389
  • [32] Ultra-Low Dosage Regimen of Rituximab in Autoimmune Blistering Skin Conditions
    Alaibac, Mauro
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [33] Status epilepticus suspected autoimmune: Neuronal surface antibodies and main clinical features
    Suga, Hiroki
    Yanagida, Atsuko
    Kanazawa, Naomi
    Ohara, Hiroya
    Kitagawa, Tadashi
    Hayashi, Masahiro
    Onozawa, Yuya
    Nagata, Naomi
    Kaneko, Juntaro
    Kitamura, Eiji
    Nishiyama, Kazutoshi
    Iizuka, Takahiro
    EPILEPSIA, 2021, 62 (11) : 2719 - 2731
  • [34] Low-dose rituximab in adult patients with primary immune thrombocytopenia
    Zaja, Francesco
    Vianelli, Nicola
    Volpetti, Stefano
    Battista, Marta Lisa
    Defina, Marzia
    Palmieri, Salvatore
    Bocchia, Monica
    Medeot, Marta
    De Luca, Stefano
    Ferrara, Felicetto
    Isola, Miriam
    Baccarani, Michele
    Fanin, Renato
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 85 (04) : 329 - 334
  • [35] Neuronal surface antigen-specific immunostaining pattern on a rat brain immunohistochemistry in autoimmune encephalitis
    Nagata, Naomi
    Kanazawa, Naomi
    Mitsuhata, Tomomi
    Iizuka, Masaki
    Nagashima, Makoto
    Nakamura, Masaaki
    Kaneko, Juntaro
    Kitamura, Eiji
    Nishiyama, Kazutoshi
    Iizuka, Takahiro
    FRONTIERS IN IMMUNOLOGY, 2023, 13
  • [36] Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis
    Cunquero, Marina
    Aguilar, Esther
    Loza-Alvarez, Pablo
    Planaguma, Jesus
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2022, (184):
  • [37] Low-Dose Rituximab for Active Moderate to Severe Graves' Orbitopathy Resistant to Conventional Treatment
    Du Pasquier-Fediaevsky, Laurence
    Andrei, Stefan
    Berche, Michel
    Leenhardt, Laurence
    Heron, Emmanuel
    Riviere, Sebastien
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2019, 27 (05) : 844 - 850
  • [38] Long-term and low-dose rituximab treatment for chronic inflammatory demyelinating polyneuropathy
    Zheng, Yongsheng
    Sun, Chong
    Zhao, Yanyin
    Meng, Quanhua
    Hu, Jianian
    Qiao, Kai
    Sun, Jian
    Xi, Jianying
    Luo, Sushan
    Lu, Jiahong
    Zhao, Chongbo
    Lin, Jie
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2024, 29 (03) : 350 - 355
  • [39] Successful treatment of refractory erythrodermic pemphigus foliaceus with low-dose rituximab and intravenous immunoglobulin
    Jiawen Zhang
    Chengfeng Zhang
    Zhongyi Xu
    Jun Liang
    Qinyuan Zhu
    Inflammation Research, 2025, 74 (1)
  • [40] Reduced-Intensity Conditioning Regimen Combined with Low-Dose Total Body Irradiation in the Treatment of Myelodysplastic Syndrome
    Lee, Sung-Eun
    Lim, Jihyang
    Yahng, Seung-Ah
    Cho, Byung-Sik
    Eom, Ki-Seong
    Kim, Myungshin
    Kim, Yoo-Jin
    Kim, Hee-Je
    Min, Chang-Ki
    Lee, Seok
    Kim, Dong-Wook
    Lee, Jong-Wook
    Min, Woo-Sung
    Park, Chong-Won
    Cho, Seok-Goo
    ACTA HAEMATOLOGICA, 2011, 126 (01) : 21 - 29